|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
25% of breast cancer cases displayed LOH for at least one studied marker in the RAD51 region exclusively.
|
17180310 |
2007 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
RAD51 [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.70-0.94, P = 0.0050] and FANCD2 expression (HR 1.50, 95% CI 1.28-1.76, P = 1.50 × 10(-7)) were associated with breast cancer survival.
|
23897704 |
2013 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
RAD51 135G>C showed statistically significant association of CC genotype and increased breast cancer risk (OR 10.28, 95 % CI 1.12-94.5) in hereditary group of patients compared to the control group.
|
24114315 |
2014 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
RAD51-C allele was associated with BC risk (2.03 (1.26-3.30) 0.002) in BQC.
|
24604328 |
2014 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
|
29635390 |
2018 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2.
|
9405383 |
1997 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A consortium of laboratories (CIMBA) has recently confirmed the RAD51 135 G/C variant as a BC risk modifier in BRCA2 mutation carriers, though not in BRCA1 carriers.
|
18283561 |
2008 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A preliminary report suggested that a single nucleotide polymorphism in the 5' untranslated region of RAD51 (135C/G) increases breast cancer risk in BRCA1 and BRCA2 carriers.
|
11248061 |
2001 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
A significant proportion of BRCA1 tumours were positive for PARP1 (non-cleaved), and negative for BARD1 and RAD51 compared with sporadic BC.
|
25690937 |
2015 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A single nucleotide polymorphism in the 5'- untranslated region of RAD51 (a G to C substitution at position 135, the G/C polymorphism) is reported to modulate breast cancer risk.
|
12673366 |
2003 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A specific RAD51 haplotype increases breast cancer risk in Jewish non-Ashkenazi high-risk women.
|
16624550 |
2006 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
A subset of DNA repair proteins such as Breast cancer gene 1 (BRCA1), BRCA2 and RecA homolog (RAD51) are client proteins of heat shock protein 90 (Hsp90).
|
28111726 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Abnormally elevated RAD51 function and hyperactive homologous recombination (HR) rates have been found in a panel of cancers, including breast cancer and chronic myeloid leukaemia (CML).
|
23341130 |
2013 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Additionally, we verified an increased risk of breast cancer in women with FH and carrying RAD51 135C genotypes (OR = 2.17 95% CI 1.19-3.98; p = 0.012).
|
17063276 |
2007 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Altogether, our data suggest that RAD51 tolerates so little dysfunctional sequence variation that rare variants in the gene contribute little, if anything, to breast cancer susceptibility.
|
23300655 |
2012 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Both FBC and OBC induced oxidative DNA damage and time-dependent DNA repair responses with increased gene expressions of breast cancer susceptibility protein 1 (<i>brca1</i>), recombination protein A paralog B (<i>rad51b</i>), methyl methanesulfonate-sensitivity protein 22-like and tonsoku-like (<i>mms22l</i>).
|
30931099 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Combined risk genotype analysis revealed that Rad51 SNPs enhance BC risk in BRCA2 patients, whereas Xrcc3 SNPs significantly enhance BC risk in carriers of BRCA1 mutations and in patients with hereditary BC.
|
21725594 |
2011 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Consequently, these results demonstrate that inhibition of Rad51 can sensitize BT549 cells with wild type PTEN to olaparib, which would contribute to using PARP inhibitors in individual treatment of breast cancer patients with PTEN variations.
|
28759753 |
2017 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
DACH1 repressed p21CIP1 and induced RAD51, an association found in basal breast cancer.
|
23798621 |
2013 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Due to the severity of phenotype and the integrity of exon 11 encoding RAD51 binding domain, and the fact that the patient's mother also had breast cancer at her 60s, we speculate a possible coexistence of maternal breast cancer risk allele(s).Embryo biopsy was performed on day 3.
|
25304112 |
2014 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Germline DNA from 1054 BRCA-mutation-negative Hispanic women with hereditary BC (BC diagnosed at age <51 years, bilateral BC, breast and ovarian cancer, or BC diagnosed at ages 51-70 years with ≥2 first-degree or second-degree relatives who had BC diagnosed at age <70 years), 312 local controls, and 887 multiethnic cohort controls was sequenced and analyzed for 12 known and suspected, high-penetrance and moderate-penetrance cancer susceptibility genes (ataxia telangiectasia mutated [ATM], breast cancer 1 interacting protein C-terminal helicase 1 [BRIP1], cadherin 1 [CDH1], checkpoint kinase 2 [CHEK2], nibrin [NBN], neurofibromatosis type 1 [NF1], partner and localizer of BRCA2 [PALB2], phosphatase and tensin homolog [PTEN], RAD51 paralog 3 [RAD51C], RAD51D, serine/threonine kinase 11 [STK11], and TP53).
|
31206626 |
2019 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here, we describe a role for RAD51 in driving genomic instability caused by impaired replication and intra-S mediated CHK1 signaling by studying an inducible RAD51 overexpression model as well as 10 breast cancer cell lines.
|
26317153 |
2015 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Identification of Rad51 alteration in patients with bilateral breast cancer.
|
10807537 |
2000 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
In breast cancer cells, PTEN inhibition represses nuclear translocation of breast cancer susceptibility 1 (BRCA1) and Rad51; this impairs DNA repair resulting in an accumulation of damaged DNA, which contributes to cell senescence.
|
30521029 |
2019 |